Articles
Multiple Myeloma Research Foundation Live Event: Precision Medicine and Big Data in Multiple Myeloma
In this continuing education activity, frequently asked questions gathered from the community will be addressed to myeloma experts.
Multiple Myeloma Research Foundation Live Event: Precision Medicine and Big Data in Multiple Myeloma
In this continuing education activity, frequently asked questions gathered from the community will be addressed to myeloma experts.
Onco360, the largest independent provider of Oncology Pharmacy Services in the U.S., announced today that Bill Gittinger has joined the organization as a National Director for its Managed Care business.
The Cancer Genome Atlas (TCGA) project now includes a recently reported comprehensive molecular characterization of muscle-invasive urothelial bladder carcinoma.
Immunotherapy with ipilimumab improved progression-free survival (PFS) and prostate-specific antigen response compared with placebo, but improvement in overall survival (OS) failed to reach statistical significance in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC). These results of a randomized phase 3 trial (CA184-043) were presented at the 2014 Genitourinary Cancers Symposium.
By Phoebe Starr
Enzalutamide prolonged survival and delayed radiographic progression of disease in men who had not received chemotherapy for metastatic castration-resistant prostate cancer (mCRPC), according to complete results from the phase 3 PREVAIL trial.
By Wayne Kuznar
Phase 3 data from a global clinical trial indicated an improvement in overall survival (OS) when the investigational angiogenesis inhibitor ramucirumab was added to chemotherapy as second-line therapy in patients with advanced gastric cancer.
With little information in the literature, pharmacists and oncologists may feel insecure about the use of chemotherapy in a pregnant patient.
By Wayne Kuznar
Recent advances in molecular technologies have enabled the dissection of inhibitory pathways within tumors and identification of inflammatory signals within the tumor microenvironment that regulate host immune responses.
In 2010, Dr Thomas Frieden, director of the Centers for Disease Control and Prevention (CDC), chose the 6 original health priorities that he would call “winnable battles.”